. 2014 Mar 4;171(6):1448–1461. doi: 10.1111/bph.12545

Table 1.

Levels of inflammatory mediators (pg·mL⁻¹) in extracts of the iris and ciliary body

	Control	LPS	LPS + HU308	LPS + AM630	LPS + AM630 + HU308
TNF-α	5.9 ± 4.1^*	52.6 ± 18.12⁺	0.82 ± 0.6^*	16.8 ± 7.1^*	5.9 ± 4.2^*
IL-1β	264.2 ± 71.4^*	5572 ± 1076⁺	603 ± 214^*	3564 ± 1453⁺	550 ± 137^*
IL-6	8.9 ± 2.2^*	32.9 ± 5.1⁺	7.5 ± 2.3^*	16.5 ± 3.7^*	7.2 ± 2.3^*
IL-10	11.1 ± 1.8	18 ± 1.5	6.9 ± 1.3^*	14.2 ± 3.0	12.9 ± 2.7
IFN-γ	1.3 ± 0.4	2.5 ± 3.8	0.8 ± 0.4^*	1.4 ± 0.4	1.2 ± 0.6
CCL5	53.2 ± 17.9^*	289 ± 49⁺	66.2 ± 17.1^*	192 ± 57.3⁺	51.1 ± 13.2^*
CXCL2	101 ± 34.6^*	2023 ± 418⁺	213 ± 58.7^*	852 ± 362^*	288 ± 102^*
sVCAM	214 ± 34.3	363 ± 50.5	191 ± 27.1	360 ± 82	244 ± 43.4
ICAM	1304 ± 234	2118 ± 368	1208 ± 116	2333 ± 557	1589 ± 271

Data shown (mean ± SEM) are from control, LPS and LPS with treatments with CB receptor ligands: CB₂ receptor agonist, HU308, CB₂ receptor antagonist AM630 and combination of AM630 + HU308, n = 8–11,P < 0.05 to control, ^*P < 0.05 compared with LPS.